Humana associate Dana Drzayich Antol, MS, a research consultant with Comprehensive Health Insights, recently won first place in the Psychosocial Support category for her team’s poster presentation at the Academy of Oncology Nurse & Patient Navigators’ (AONN+) Seventh Annual Navigation & Survivorship Conference in Las Vegas.
The team’s presentation — which was a combined effort between employees of Humana and Genentech Inc. — showed social support to be a moderator in the relationship between comorbidity medication adherence and health-related quality of life (HRQOL) for patients with metastatic cancer. Co-authors of this presentation included: Adrianne W. Casebeer, PhD, MPP, MS; Sari Hopson, PhD, MSPH; Raya Khoury, MPH; Aparna Parikh, MD; Alisha Stein, RN-NC, MSN, OCN; Todd Michael, PharmD, RPH; Stephen Stemkowski, PhD, MHA; and Mikele Bunce, PhD, MPH.
The study assessed HRQOL by having participants complete the Centers for Disease Control and Prevention’s Healthy Days survey. On its own, low comorbidity medication adherence adversely impacted the patients’ number of healthy days. The association between comorbidity medication adherence and the reduction in the number of healthy days was further amplified in the presence of patient-perceived fair or poor social support. These findings have important implications for improving or preserving the quality of life for patients with cancer.
The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. The organization, which has more than 5,000 members, was founded in 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services in order to better manage the complexities of the cancer treatment process.